View ValuationXtalPi Holdings 향후 성장Future 기준 점검 5/6XtalPi Holdings (는) 각각 연간 62.4% 및 26.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 62.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6% 로 예상됩니다.핵심 정보62.4%이익 성장률62.40%EPS 성장률Life Sciences 이익 성장17.6%매출 성장률26.4%향후 자기자본이익률5.98%애널리스트 커버리지Low마지막 업데이트30 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.공시 • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen China공시 • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026공시 • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.공시 • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing공시 • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing공시 • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025공시 • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.이익 및 매출 성장 예측OTCPK:QNTP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20281,736588N/A804212/31/20271,336332N/A110312/31/202687838N/A454212/31/2025803124-247-165N/A9/30/2025742-37-365-292N/A6/30/2025681-197-483-418N/A3/31/2025474-857-512-448N/A12/31/2024266-1,517-541-479N/A9/30/2024232-2,027-612-523N/A6/30/2024197-2,538-684-568N/A3/31/2024186-2,226-691-568N/A12/31/2023174-1,914-698-568N/A12/31/2022133-1,439-628-429N/A12/31/202163-2,137-417-254N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: QNTP.F 의 연간 예상 수익 증가율(62.4%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: QNTP.F 의 연간 수익(62.4%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: QNTP.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: QNTP.F 의 수익(연간 26.4%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: QNTP.F 의 수익(연간 26.4%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: QNTP.F의 자본 수익률은 3년 후 6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 11:31종가2026/05/15 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스XtalPi Holdings Limited는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yu WuCMB International Securities LimitedWing-Tai NgDeutsche BankYue-Kwong LuiJefferies LLC2명의 분석가 더 보기
공시 • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.
공시 • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen China
공시 • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026
공시 • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.
공시 • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
공시 • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
공시 • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025
공시 • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.